MoneyWorks4Me

Lupin spurts on reporting 51% rise in FY13 consolidated net profit

08 May 2013 Evaluate

Lupin is currently trading at Rs 726.00, up by 12.65 points or 1.77% from its previous closing of Rs 713.35 on the BSE.

The scrip opened at Rs 720.40 and has touched a high and low of Rs 738.80 and Rs 720.40 respectively. So far 286206 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 718.00 on 07-May-2013 and a 52 week low of Rs 507.00 on 18-Jun-2012.

Last one week high and low of the scrip stood at Rs 718.00 and Rs 695.10 respectively. The current market cap of the company is Rs 32449.21 crore.

The promoters holding in the company stood at 46.84% while Institutions and Non-Institutions held 43.13% and 10.04% respectively.

For the year, the Company’s net profit grew by 56.70% at Rs 1260.43 crore as compared to Rs 804.37 crore for the year ended March 31, 2012. Its total income has increased by 32.61% to Rs 7145.82 crore for the year from Rs 5388.32 crore for the previous year.

On consolidated basis, the group’s net profit after taxes, minority interest stood at Rs 1314.16 crore for the FY13 as compared to Rs 867.65 crore in FY12, up by 51.46%. Groups’s total Income has increased by 36.24% to Rs 9669.15 crore for the year under review from Rs 7097.26 crore for the previous year.

Lupin’s board of directors at its meeting held on May 08, 2013, inter alia, has recommended dividend at the rate of 200% i.e. Rs. 4 per equity shares of the face value of Rs 2 each for the year ended March 31, 2013.

Peers
Company Name CMP
Sun Pharma. Inds. 1860.00
Dr. Reddys Labs. 1250.00
Cipla 1383.00
Lupin 2060.00
Zydus Lifesciences 1195.20
View more..